Artiva Biotherapeutics, Inc. ARTV Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s operating lease liabilities?
- Artiva Biotherapeutics, Inc. (ARTV) reported operating lease liabilities of $7.23M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Artiva Biotherapeutics, Inc.'s operating lease liabilities decreased by 29.6% year-over-year, from $10.27M to $7.23M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s operating lease liabilities?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s operating lease liabilities has grown at a -23.1% compound annual growth rate (CAGR), from $13.32M to $7.88M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.